|
A.A. Zimichev, D.O. Gusev, D.Yu. Lukyanova
Evaluation of the efficacy of silodosin 8 mg in comorbid patients with LUTS/BPH
|
№6 / 2022
|
|
A.G. Martov, A.S. Dukhanin, A.N. Bernikov
Current issues in alpha1-adrenergic blocker therapy: integration of pharmacological approach and clinical experience
|
№3 / 2022
|
|
G.G. Krivoborodov, E.I. Tur
Efficiency and safety of silodosin for treatment of lower urinary tract symptoms, associated of benign prostatic hyperplasia
|
№2 / 2019
|
|
D.Yu. Pushkar, A.N. Bernikov, A.V. Sadchenko
Silodosin in the Treatment of Patients with Benign Prostatic Hyperplasia – Results of Russian Multicenter Observational Study
|
№5 / 2015
|
|
R.M. Kadiev, T.I. Derevyanko
Experience of the use of drug urorec: efficacy and safety
|
№3 / 2014
|
|
Kogan M.I., Kireev A.Yu.
Results of treatment of patients with prostatic adenoma using silodosin based on an assessment of the phenotype of male sexuality
|
№6 / 2013
|
|
Neymark A.I., Nozdrachyov N.A.
Experience of the use of silodosin in acute urinary retention caused by benign prostatic hyperplasia
|
№4 / 2013
|
|
F. Montorsi.
Pharmacological profile of silodosin
|
№2 / 2013
|
Русский
